ActoveginАктовегин
A deproteinized calf-blood hemoderivative, a mixture of low-molecular-weight constituents obtained after protein removal. Human trials have examined diabetic neuropathy and cognitive impairment after stroke.
What the studies found
Review of earlier studies · 2022
Actovegin in the management of patients after ischemic stroke: A systematic review.
The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
Study notes · methods, sources and limitations
Participants or model Five controlled studies after ischemic stroke; one randomized trial and four observational studies
Important limitations
- Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.
PloS one · Journal publication
Randomized study in people · 2017
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
- ADAS-cog+ change at month 6
- −6.8 Actovegin versus −4.6 placebo
- Estimated treatment difference
- −2.3 points; 95% CI −3.9 to −0.7p=0.005
- Recurrent ischemic stroke
- More frequent with Actovegin, not statistically significantEvent counts absent from abstract
The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.
Study notes · methods, sources and limitations
Participants or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
Design ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.
Important limitations
- Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.
- Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.
Stroke · Journal publication
Randomized study in people · 2009
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
- TSS exposure-adjusted difference
- −0.56 points; 95% CI −0.85 to −0.27p=0.0003
- TSS baseline-to-day-160 difference
- −0.86 points; 95% CI −1.22 to −0.50p<0.0001
- Vibration threshold, exposure-adjusted
- 3% decrease; 95% CI 0–6%p=0.084
Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.
More reported outcomes
- Vibration threshold at day 160
- 5% decrease; 95% CI 1–9%p=0.017
- NIS-LL sensory function
- −0.25; 95% CI −0.46 to −0.04p=0.021
- Adverse-event incidence
- No between-group difference reported
Study notes · methods, sources and limitations
Participants or model 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
Design 567 diabetic-neuropathy patients: Actovegin 281 versus placebo 286. Twenty IV infusions 2,000 mg/day, then oral 1,800 mg/day for 140 days; total 160 days.
Important limitations
- Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.
- The nonsignificant exposure-adjusted vibration endpoint is preserved alongside the significant end-of-study result.
Diabetes care · Journal publication
About Actovegin
Names in this research collection
Aktovegin
Identity / background source ↗
Research background
Clinical research in diabetic polyneuropathy and post-stroke cognitive impairment. Proposed metabolic effects do not establish protection from hypoxia, enhanced performance or general tissue regeneration.
- Compound class
- Deproteinized blood-derived preparation
- Research collection
- Related nootropics & combinations · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Two randomized trials and a stroke systematic review linked below
Study methods
Mixed endpoints; statistical and clinical significance distinguished
Independent replication
Stroke review reuses ARTEMIDA; independent confirmation remains needed
Source access
Indexed abstracts with links to original publications
Safety evidence
Stroke safety imbalance and uncertain benefit require attention; long-term safety not established here
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2015
Actovegin: diabetic neuropathy use — EA021189B1
Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.
Total Symptom Score: end-to-baseline change · −5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86 · Actovegin versus placebo · End of study · 95% CI −1.22 to −0.50; p<0.0001
Study notes and original source
Actovegin: diabetic neuropathy use — EA021189B1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Лусине Моусесьян · EA021189B1 · patent family 41345991
Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.
Results and tables
Reported patent results
Reported findings
Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.
Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.
Population or model Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total Symptom Score: end-to-baseline change | −5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86 | Actovegin versus placebo · End of study · 95% CI −1.22 to −0.50; p<0.0001 |
| Time-averaged vibration threshold | Ratio 0.97 | Actovegin versus placebo · During treatment · 95% CI 0.94–1.00; p=0.084 |
| Lower-limb neuropathy score | Adjusted difference −0.48 | Actovegin versus placebo · End-of-study change · Table 5: p=0.080; CI −1.01 to 0.06. A later table inconsistently prints p=0.008. |
| Reported adverse events | 186 active versus 198 placebo events; serious events 10 in 7 active patients versus 11 in 10 placebo patients | Event counts are not numbers of affected patients |
Patent tables contain OCR/sign and p-value inconsistencies; the repeated TSS contrast and its interval were cross-checked across tables. Neutral primary/secondary findings are retained and no independent-trial count is added.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Related trial publications and patent descriptions must not be counted as independent clinical replications.
- Patent tables contain OCR/sign and p-value inconsistencies; the repeated TSS contrast and its interval were cross-checked across tables. Neutral primary/secondary findings are retained and no independent-trial count is added.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Review of earlier studies · 2022
Actovegin in the management of patients after ischemic stroke: A systematic review.
The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
Study notes and original source
Actovegin in the management of patients after ischemic stroke: A systematic review.
Deproteinized calf-blood derivative · Journal publication
la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D · PloS one
The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
- Population / setting
- Five controlled studies after ischemic stroke; one randomized trial and four observational studies
- Source reviewed
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
- Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.
Reviewed 2026-09-30.
Randomized study in people · 2017
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.
ADAS-cog+ change at month 6 · −6.8 Actovegin versus −4.6 placebo
Study notes and original source
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
Deproteinized calf-blood derivative · Journal publication
Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD · Stroke
The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.
Results and tables
Reported findings and study design
ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.
Population or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
Dose, route and schedule
Actovegin: 2,000 mg/day for up to 20 intravenous infusions, followed by 1,200 mg/day orally, for six months of treatment in total. Treatment began within one week of ischemic stroke.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ADAS-cog+ change at month 6 | −6.8 Actovegin versus −4.6 placebo | |
| Estimated treatment difference | −2.3 points; 95% CI −3.9 to −0.7 | p=0.005 |
| Recurrent ischemic stroke | More frequent with Actovegin, not statistically significant | Event counts absent from abstract |
Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
- Source reviewed
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
- Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.
Reviewed 2026-09-30.
Randomized study in people · 2009
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.
TSS exposure-adjusted difference · −0.56 points; 95% CI −0.85 to −0.27 · p=0.0003
Study notes and original source
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
Deproteinized calf-blood derivative · Journal publication
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I · Diabetes care
Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.
Results and tables
Reported findings and study design
567 diabetic-neuropathy patients: Actovegin 281 versus placebo 286. Twenty IV infusions 2,000 mg/day, then oral 1,800 mg/day for 140 days; total 160 days.
Population or model 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
Dose, route and schedule
Actovegin: 20 intravenous infusions at 2,000 mg/day, followed by oral treatment at 1,800 mg/day for 140 days in diabetic polyneuropathy.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| TSS exposure-adjusted difference | −0.56 points; 95% CI −0.85 to −0.27 | p=0.0003 |
| TSS baseline-to-day-160 difference | −0.86 points; 95% CI −1.22 to −0.50 | p<0.0001 |
| Vibration threshold, exposure-adjusted | 3% decrease; 95% CI 0–6% | p=0.084 |
| Vibration threshold at day 160 | 5% decrease; 95% CI 1–9% | p=0.017 |
| NIS-LL sensory function | −0.25; 95% CI −0.46 to −0.04 | p=0.021 |
| Adverse-event incidence | No between-group difference reported |
The nonsignificant exposure-adjusted vibration endpoint is preserved alongside the significant end-of-study result.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
- Source reviewed
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
- Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.
Reviewed 2026-09-30.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗